Arypsa (APYI) Stock Price

Arypsa Price

NYSE·CLOSED
0.00USD+0.00 (+0.00 %)
Market closed

Over the last 19 years Arypsa grew revenue by 3.5% annually, reaching 8.53 M USD. Earnings per share have declined at 2.3% per year over the last 14 years. For Arypsa, the net margin of -60.9% is down versus -11.0% a few years ago.

Arypsa stock price

Volume
Details

Stock Price

How to Read This Chart

This chart tracks the historical stock price of Arypsa over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Arypsa stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Arypsa's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Arypsa Stock Price History
DateArypsa Price
7/23/20260.00 USD
7/22/20260.00 USD
7/21/20260.00 USD
7/20/20260.00 USD
7/17/20260.00 USD
7/16/20260.00 USD
7/15/20260.00 USD
7/14/20260.00 USD
7/13/20260.00 USD
7/10/20260.00 USD
7/9/20260.00 USD
7/8/20260.00 USD
7/7/20260.00 USD
7/6/20260.00 USD
7/2/20260.00 USD
7/1/20260.00 USD
6/30/20260.00 USD
6/29/20260.00 USD
6/26/20260.00 USD
6/25/20260.00 USD
6/24/20260.00 USD
6/23/20260.00 USD
6/22/20260.00 USD
6/18/20260.00 USD
6/17/20260.00 USD
6/16/20260.00 USD
6/15/20260.00 USD
6/12/20260.00 USD
6/11/20260.00 USD
6/10/20260.00 USD
6/9/20260.00 USD
6/8/20260.00 USD
6/5/20260.00 USD
6/4/20260.00 USD
6/3/20260.00 USD
6/2/20260.00 USD
6/1/20260.00 USD
5/29/20260.00 USD
5/28/20260.00 USD
5/27/20260.00 USD
5/26/20260.00 USD
5/22/20260.00 USD
5/21/20260.00 USD
5/20/20260.00 USD
5/19/20260.00 USD
5/18/20260.00 USD
5/15/20260.00 USD
5/14/20260.00 USD
5/13/20260.00 USD
5/12/20260.00 USD
5/11/20260.00 USD
5/8/20260.00 USD
5/7/20260.00 USD
5/6/20260.00 USD
5/5/20260.00 USD
5/4/20260.00 USD
5/1/20260.00 USD
4/30/20260.00 USD
4/29/20260.00 USD
4/28/20260.00 USD
4/27/20260.00 USD
4/24/20260.00 USD
4/23/20260.00 USD
4/22/20260.00 USD
4/21/20260.00 USD
4/20/20260.00 USD
4/17/20260.00 USD
4/16/20260.00 USD
4/15/20260.00 USD
4/14/20260.00 USD
4/13/20260.00 USD
4/10/20260.00 USD
4/9/20260.00 USD
4/8/20260.00 USD
4/7/20260.00 USD
4/6/20260.00 USD
4/2/20260.00 USD
4/1/20260.00 USD
3/31/20260.00 USD
3/30/20260.00 USD
3/27/20260.00 USD
3/26/20260.00 USD
3/25/20260.00 USD
3/24/20260.00 USD
3/23/20260.00 USD
3/20/20260.00 USD
3/19/20260.00 USD
3/18/20260.00 USD
3/17/20260.00 USD
3/16/20260.00 USD
3/13/20260.00 USD
3/12/20260.00 USD
3/11/20260.00 USD
3/10/20260.00 USD
3/9/20260.00 USD
3/6/20260.00 USD
3/5/20260.00 USD
3/4/20260.00 USD
3/3/20260.00 USD
3/2/20260.00 USD
2/27/20260.00 USD
2/26/20260.00 USD
2/25/20260.00 USD
2/24/20260.00 USD
2/23/20260.00 USD
2/20/20260.00 USD
2/19/20260.00 USD
2/18/20260.00 USD
2/17/20260.00 USD
2/13/20260.00 USD
2/12/20260.00 USD
2/11/20260.00 USD
2/10/20260.00 USD
2/9/20260.00 USD
2/6/20260.00 USD
2/5/20260.00 USD
2/4/20260.00 USD
2/3/20260.00 USD
2/2/20260.00 USD
1/30/20260.00 USD
1/29/20260.00 USD
1/28/20260.00 USD
1/27/20260.00 USD
1/26/20260.00 USD
1/23/20260.00 USD
1/22/20260.00 USD
1/21/20260.00 USD
1/20/20260.00 USD
1/16/20260.00 USD
1/15/20260.00 USD
1/14/20260.00 USD
1/13/20260.00 USD
1/12/20260.00 USD
1/9/20260.00 USD
1/8/20260.00 USD
1/7/20260.00 USD
1/6/20260.00 USD
1/5/20260.00 USD
1/2/20260.00 USD
12/31/20250.00 USD
12/30/20250.00 USD
12/29/20250.00 USD
12/26/20250.00 USD
12/24/20250.00 USD
12/23/20250.00 USD
12/22/20250.00 USD
12/19/20250.00 USD
12/18/20250.00 USD
12/17/20250.00 USD
12/16/20250.00 USD
12/15/20250.00 USD
12/12/20250.00 USD
12/11/20250.00 USD
12/10/20250.00 USD
12/9/20250.00 USD
12/8/20250.00 USD
12/5/20250.00 USD
12/4/20250.00 USD
12/3/20250.00 USD
12/2/20250.00 USD
12/1/20250.00 USD
11/28/20250.00 USD
11/26/20250.00 USD
11/25/20250.00 USD
11/24/20250.00 USD
11/21/20250.00 USD
11/20/20250.00 USD
11/19/20250.00 USD
11/18/20250.00 USD
11/17/20250.00 USD
11/14/20250.00 USD
11/13/20250.00 USD
11/12/20250.00 USD
11/11/20250.00 USD
11/10/20250.00 USD
11/7/20250.00 USD
11/6/20250.00 USD
11/5/20250.00 USD
11/4/20250.00 USD
11/3/20250.00 USD
10/31/20250.00 USD
10/30/20250.00 USD
10/29/20250.00 USD
10/28/20250.00 USD
10/27/20250.00 USD
10/24/20250.00 USD
10/23/20250.00 USD
10/22/20250.00 USD
10/21/20250.00 USD
10/20/20250.00 USD
10/17/20250.00 USD
10/16/20250.00 USD
10/15/20250.00 USD
10/14/20250.00 USD
10/13/20250.00 USD
10/10/20250.00 USD
10/9/20250.00 USD
10/8/20250.00 USD
10/7/20250.00 USD
10/6/20250.00 USD
10/3/20250.00 USD
10/2/20250.00 USD
10/1/20250.00 USD
9/30/20250.00 USD
9/29/20250.00 USD
9/26/20250.00 USD
9/25/20250.00 USD
9/24/20250.00 USD
9/23/20250.00 USD
9/22/20250.00 USD
9/19/20250.00 USD
9/18/20250.00 USD
9/17/20250.00 USD
9/16/20250.00 USD
9/15/20250.00 USD
9/12/20250.00 USD
9/11/20250.00 USD
9/10/20250.00 USD
9/9/20250.00 USD
9/8/20250.00 USD
9/5/20250.00 USD
9/4/20250.00 USD
9/3/20250.00 USD
9/2/20250.00 USD
8/29/20250.00 USD
8/28/20250.00 USD
8/27/20250.00 USD
8/26/20250.00 USD
8/25/20250.00 USD
8/22/20250.00 USD
8/21/20250.00 USD
8/20/20250.00 USD
8/19/20250.00 USD
8/18/20250.00 USD
8/15/20250.00 USD
8/14/20250.00 USD
8/13/20250.00 USD
8/12/20250.00 USD
8/11/20250.00 USD
8/8/20250.00 USD
8/7/20250.00 USD
8/6/20250.00 USD
8/5/20250.00 USD
8/4/20250.00 USD
8/1/20250.00 USD
7/31/20250.00 USD
7/30/20250.00 USD
7/29/20250.00 USD
7/28/20250.00 USD
7/25/20250.00 USD
Access this data via the Eulerpool API

Arypsa Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2001
7.83 M USD
720,000.00 USD
430,000.00 USD
Jan 1, 2002
7.38 M USD
130,000.00 USD
90,000.00 USD
Jan 1, 2003
7.66 M USD
279,000.00 USD
162,000.00 USD
Jan 1, 2004
2.39 M USD
-266,000.00 USD
-263,000.00 USD
Jan 1, 2005
7.21 M USD
-1.68 M USD
-2.50 M USD
Jan 1, 2006
12.69 M USD
-3.34 M USD
-3.57 M USD
Jan 1, 2007
10.27 M USD
-4.20 M USD
-5.01 M USD
Jan 1, 2008
8.53 M USD
-4.13 M USD
-5.19 M USD

Arypsa Income Statement, Balance Sheet, Cash Flow Statement

Last updated Jul 24, 2026, 8:19 PM
 
REVENUEM USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM USD
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESk
1993199419951996199719981999200020012002200320042005200620072008
5.005.006.007.006.008.007.005.007.007.007.002.007.0012.0010.008.00
-16.6720.0016.67-14.2933.33-12.50-28.5740.00-71.43250.0071.43-16.67-20.00
40.0040.0050.0042.8633.3350.0028.5740.0057.1442.8657.1450.0042.8641.6740.0037.50
2.002.003.003.002.004.002.002.004.003.004.001.003.005.004.003.00
-1.00-3.00-4.00-4.00
-14.29-25.00-40.00-50.00
-2.00-3.00-5.00-5.00
50.0066.67
30.0030.0030.0030.0030.0030.0030.0030.0030.0030.0034.3032.9040.0098.20112.20123.10
Details

Income Statement Key Figures

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Arypsa generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Arypsa retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Arypsa's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Arypsa has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Arypsa's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Arypsa stock margins

The Arypsa margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Arypsa. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Arypsa.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2001
54.28 %
9.20 %
5.49 %
Jan 1, 2002
51.63 %
1.76 %
1.22 %
Jan 1, 2003
54.19 %
3.64 %
2.12 %
Jan 1, 2004
51.82 %
-11.13 %
-11.00 %
Jan 1, 2005
48.71 %
-23.37 %
-34.73 %
Jan 1, 2006
46.38 %
-26.34 %
-28.13 %
Jan 1, 2007
47.43 %
-40.86 %
-48.72 %
Jan 1, 2008
45.94 %
-48.39 %
-60.87 %

Arypsa Stock Revenue, EBIT, Earnings per Share

The Arypsa earnings per share therefore indicates how much revenue Arypsa has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2001
26,361.00 USD
2,424.00 USD
1,447.67 USD
Jan 1, 2002
24,846.00 USD
437.67 USD
303.00 USD
Jan 1, 2003
22,543.91 USD
821.55 USD
477.03 USD
Jan 1, 2004
7,340.15 USD
-816.60 USD
-807.39 USD
Jan 1, 2005
18,195.15 USD
-4,252.10 USD
-6,320.08 USD
Jan 1, 2006
13,051.83 USD
-3,438.32 USD
-3,671.79 USD
Jan 1, 2007
9,246.63 USD
-3,778.05 USD
-4,505.39 USD
Jan 1, 2008
6,995.34 USD
-3,385.26 USD
-4,258.25 USD

Arypsa business model & stock analysis

Aspyra Inc. is an American company based in California that specializes in the development and distribution of medical IT solutions. The history of Aspyra dates back to 1993 when the company was founded as an independent provider of medical imaging technology. In the following years, Aspyra expanded its business model and focused on developing integrated solutions for the healthcare industry. Today, the company offers a wide range of products and services such as RIS, PACS, LIS, and teleradiology systems that are used by hospitals, clinics, and medical practices worldwide. Aspyra also has specialized divisions within the company that focus on specific solutions. One of these divisions is INSIGHT, which specializes in the development of LIS systems. These solutions provide a specialized software platform that simplifies laboratory management and the workflow of medical tests and results. Another important division of Aspyra is the teleradiology department, which transmits specialized medical imaging findings and reports via telecommunication systems from one radiologist to another. This is particularly advantageous in providing care to patients in rural areas or areas with limited healthcare services. Aspyra also offers various software products, including the PACS system, the Radiology Information System (RIS), and the LIS system. The PACS system allows for the capture of medical images and provides them in electronic form, while the RIS system facilitates the management process of radiology departments and administrative processes related to the data. The LIS system, specifically tailored to the needs of laboratories, also supports the creation of contingency reports and better quality assurance. In recent years, Aspyra has also formed partnerships with other companies in the healthcare industry to expand its product portfolio. This includes a recent collaboration with Healthline Networks and First Databank to combine its IT systems with health data and information from third-party specialists. Aspyra has established itself as a leading provider of medical IT solutions and offers its customers a wide range of products and services. Thanks to its expertise in the healthcare industry, the company has been able to expand its presence in the global market and establish itself as an important partner for medical facilities in North America and Europe.

Arypsa SWOT Analysis

Strengths

  • Aspyra Inc has a strong track record of providing cutting-edge software solutions in the medical imaging and telemedicine industry.
  • The company has an experienced and knowledgeable team that excels in developing innovative technologies and delivering exceptional customer service.
  • Aspyra Inc possesses advanced expertise in integrating its software with a wide range of medical devices and systems, enhancing its overall value proposition.

Weaknesses

  • One of the primary weaknesses of Aspyra Inc is its heavy dependency on a limited number of key clients, making the company vulnerable to any potential loss of those clients.
  • Aspyra Inc may have limitations in terms of its financial resources, potentially limiting its ability to invest in research and development or expand its operations.
  • The company may face challenges in quickly adapting to rapidly evolving technology trends and industry standards.

Opportunities

  • The growing demand for medical imaging and telemedicine solutions presents a significant opportunity for Aspyra Inc to expand its market presence and generate higher revenues.
  • Aspyra Inc can explore strategic partnerships with other healthcare technology companies to leverage synergies and enhance its product offerings.
  • The increasing adoption of cloud-based solutions within the healthcare industry opens doors for Aspyra Inc to develop and offer scalable and secure cloud-based platforms.

Threats

  • Aspyra Inc faces intense competition from well-established players in the medical imaging and software industry, which may pose a threat to its market share.
  • Changing regulatory requirements and compliance standards in the healthcare industry can create challenges for Aspyra Inc in terms of ensuring its software remains up-to-date and compliant.
  • Economic downturns or volatility within the healthcare sector could potentially impact customer spending and reduce demand for Aspyra Inc's solutions.

Arypsa Eulerpool Fair Value

Details

Fair Value Estimate

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Arypsa historical P/E ratio, EBIT multiple, and P/S ratio

Arypsa annual returns

Details

Annual Return

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Arypsa shares outstanding

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2001
297.03 Stocks
Jan 1, 2002
297.03 Stocks
Jan 1, 2003
339.60 Stocks
Jan 1, 2004
325.74 Stocks
Jan 1, 2005
396.04 Stocks
Jan 1, 2006
972.28 Stocks
Jan 1, 2007
1,110.89 Stocks
Jan 1, 2008
1,218.81 Stocks

Arypsa stock splits

In Arypsa's history, there have been no stock splits.
Price targets and forecasts for Arypsa are not yet available.

Arypsa Executives and Management Board

AL

Ademola Lawal

(35)

Chief Executive Officer, Chief Operating Officer, Director · since 2008

Compensation137,215.00 USD
JZ

Mr. James Zierick

(54)

Chairman of the Board · since 2007

Compensation127,500.00 USD
MV

Marina Varela

(39)

Chief Accounting Officer, Corporate Secretary

JT

Jeffrey Tumbleson

(43)

Director

NC

Norman Cohen

(74)

Independent Director

Frequently asked questions about Arypsa

Aspyra Inc's business model revolves around providing innovative information technology solutions and services to healthcare organizations. As a leading provider of healthcare IT solutions, Aspyra offers a comprehensive range of products and services including laboratory information systems, picture archiving and communication systems, and revenue cycle management solutions. With a focus on enhancing efficiency, productivity, and patient care, Aspyra aims to streamline workflow processes, integrate data, and improve overall operational performance for its clients in the healthcare industry. Through its advanced technology solutions, Aspyra Inc aims to empower healthcare providers in delivering high-quality care and optimizing their business processes.

All fundamentals and in-depth analysis of Arypsa

Our stock analysis for Arypsa stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Arypsa. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.